Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 18/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 16/20 | 0.67 |
| ▸ | ADRA1B | P35368 | 16/20 | 0.67 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6729933 | 1.00 | ADRA1A (0.67) | ADRA1AADRA1DADRA1BMCHR1DRD2 | |
| SCHEMBL6727770 | 0.89 | ADRA1A (0.61) | ADRA1AADRA1DADRA1BMCHR1DRD2 | |
| SCHEMBL7518584 | 0.89 | ADRA1A (0.61) | ADRA1AADRA1DADRA1BMCHR1DRD2 | |
| SCHEMBL7082392 | 0.86 | ADRA1A (0.61) | ADRA1AADRA1DADRA1BMCHR1DRD2 | |
| SCHEMBL13939624 | 0.82 | ADRA1D (0.70) | ADRA1AADRA1DADRA1B | |
| SCHEMBL7718972 | 0.82 | ADRA1A (0.65) | ADRA1AADRA1DADRA1BMCHR1DRD2 | |
| SCHEMBL7716753 | 0.81 | ADRA1A (0.58) | ADRA1AADRA1DADRA1BMCHR1DRD2 | |
| SCHEMBL7716770 | 0.80 | ADRA1A (0.59) | ADRA1AADRA1DADRA1BMCHR1DRD2 | |
| SCHEMBL7711198 | 0.80 | ADRA1A (0.67) | ADRA1AADRA1DADRA1BMCHR1DRD2 | |
| SCHEMBL7716615 | 0.79 | ADRA1A (0.60) | ADRA1AADRA1DADRA1BMCHR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138242-A1 | Dihydropyrimidines and uses thereof | MERCK AND CO., INC. | 2004-07-15 | — | — | US | disclosed |
| US-6680323-B2 | SELECTIVE ANTAGONISTS FOR HUMAN ALPHA 1A RECEPTORS; BENIGN PROSTATIC HYPERPLASIA; (+)-1-3-((4-(3,4-DIFLUOROPHENYL)-2,5-DIOXO-1,2,5,7-TETRAHYDRO-4H-FURO(3,4 -D)PYRIMIDINE-3-CARBONYL)AMINO)-PROPYL-4-(2-PYRIDYL)-PIPERIDINE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-01-20 | — | — | US | disclosed |
| US-6274585-B1 | BENIGN PROSTATIC HYPERPLASIA TREATMENT | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138242-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | ADRA1A 4/4885ADRA1D 3/4885ADRA1B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.